Head to Head Survey: Concordia International Corp. (CXRX) versus Catalent (CTLT)
Concordia International Corp. (NASDAQ: CXRX) and Catalent (NASDAQ:CTLT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.
Earnings and Valuation
This table compares Concordia International Corp. and Catalent’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Concordia International Corp.||$677.25 million||0.09||$326.58 million||($35.65)||-0.03|
|Catalent||$2.08 billion||2.40||$407.50 million||N/A||N/A|
Catalent has higher revenue and earnings than Concordia International Corp..
Insider & Institutional Ownership
9.1% of Concordia International Corp. shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings and price targets for Concordia International Corp. and Catalent, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Concordia International Corp.||5||0||0||0||1.00|
Concordia International Corp. presently has a consensus target price of $8.00, suggesting a potential upside of 577.97%. Catalent has a consensus target price of $38.60, suggesting a potential downside of 3.31%. Given Concordia International Corp.’s higher probable upside, equities analysts clearly believe Concordia International Corp. is more favorable than Catalent.
This table compares Concordia International Corp. and Catalent’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Concordia International Corp.||-269.97%||-83.96%||-0.62%|
Catalent beats Concordia International Corp. on 8 of the 10 factors compared between the two stocks.
About Concordia International Corp.
Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Receive News & Ratings for Concordia International Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.